1.05
-0.01(-0.94%)
Currency In USD
| Previous Close | 1.06 |
| Open | 1.06 |
| Day High | 1.08 |
| Day Low | 0.99 |
| 52-Week High | 2.67 |
| 52-Week Low | 0.86 |
| Volume | 20,284 |
| Average Volume | 72,655 |
| Market Cap | 10.76M |
| PE | -1.13 |
| EPS | -0.93 |
| Moving Average 50 Days | 1.01 |
| Moving Average 200 Days | 1.29 |
| Change | -0.01 |
If you invested $1000 in Cocrystal Pharma, Inc. (COCP) 10 years ago, it would be worth $4.94 as of February 28, 2026 at a share price of $1.05. Whereas If you bought $1000 worth of Cocrystal Pharma, Inc. (COCP) shares 4 years ago, it would be worth $55.38 as of February 28, 2026 at a share price of $1.05.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026
GlobeNewswire Inc.
Feb 19, 2026 1:00 PM GMT
CDI‑988 is the first oral antiviral drug candidate being developed for prevention and treatment of norovirus infectionsCompany to present Phase 1 data and updates from ongoing Phase 1b study conducted at Emory University School of MedicineNo approved
Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus
GlobeNewswire Inc.
Dec 18, 2025 1:00 PM GMT
Subject enrollment expected to begin in Q1 2026CDI-988 is the first oral broad-spectrum antiviral drug candidate for potential prevention of norovirus outbreaks and treatment of acute viral gastroenteritis caused by norovirus infectionThere are no ap
Cocrystal Pharma to Present at the Noble Capital Markets’ 21st Emerging Growth Equity Conference
GlobeNewswire Inc.
Dec 01, 2025 1:00 PM GMT
BOTHELL, Wash., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, CFO and co-CEO, will present a Company overview and clinical progress update at NobleCon 21 – Noble